See more : Prime Impact Acquisition I (PIAI-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Soleno Therapeutics, Inc. (SLNO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soleno Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- United Alloy-Tech Company (3162.TWO) Income Statement Analysis – Financial Results
- Sparebanken Vest (SVEG.OL) Income Statement Analysis – Financial Results
- TOFLA MEGALINE INC (TFLM) Income Statement Analysis – Financial Results
- Shekhawati Poly-Yarn Limited (SPYL.NS) Income Statement Analysis – Financial Results
- Blue Safari Group Acquisition Corp. (BSGAR) Income Statement Analysis – Financial Results
Soleno Therapeutics, Inc. (SLNO)
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.55B | 1.45M | 387.56K | 0.00 | 3.00M | 0.00 |
| Cost of Revenue | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 1.51M | 352.68K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.96M | -2.21M | -2.21M | -2.19M | -2.30M | -1.92M | -1.55B | -58.52K | 34.87K | 0.00 | 3.00M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.10% | -4.03% | 9.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 25.19M | 15.27M | 21.45M | 23.19M | 16.27M | 7.18M | 3.07M | 5.18M | 4.54M | 2.24M | 2.38M | 2.47M |
| General & Administrative | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.58M | 6.74M | 6.14M | 2.67M | 1.47M | 1.13M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.73K | 1.63M | 1.74M | 252.36K | 0.00 | 0.00 |
| SG&A | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.61M | 8.37M | 7.88M | 2.92M | 1.47M | 1.13M |
| Other Expenses | 2.71M | 0.00 | 0.00 | 4.34M | 289.00K | 6.00K | -585.95K | -100.52K | -183.57K | -4.59M | -1.97K | -22.41K |
| Operating Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 13.55M | 12.19M | 5.16M | 3.85M | 3.60M |
| Cost & Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 15.06M | 12.55M | 5.16M | 3.85M | 3.60M |
| Interest Income | 2.58M | 300.00K | 110.00K | 13.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 1.77K | 3.10K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 0.00 | 4.13M | 2.86M | 2.87M |
| Depreciation & Amortization | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 19.70K | 108.23K | 28.52K | 42.11K | 43.79K |
| EBITDA | -37.03M | -21.86M | -28.70M | -30.00M | -28.48M | -9.92M | -8.07M | -6.72M | -15.80M | -5.13M | -804.86K | -3.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.30% | -1,043.96% | -3,943.82% | 0.00% | -26.83% | 0.00% |
| Operating Income | -41.38M | -24.40M | -31.53M | -36.29M | -23.49M | -14.30M | -12.17M | -13.61M | -12.16M | -5.16M | -846.78K | -3.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.78% | -938.12% | -3,137.55% | 0.00% | -28.23% | 0.00% |
| Total Other Income/Expenses | 2.40M | 330.00K | 618.00K | 11.65M | -7.29M | 2.46M | -1.27M | 1.59M | -3.75M | -8.08M | -2.86M | -2.88M |
| Income Before Tax | -38.99M | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M | -13.72M | -12.04M | -15.91M | -13.87M | -3.71M | -6.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.88% | -830.14% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| Income Tax Expense | 0.00 | -3.75M | -1.35M | -9.26M | 5.14M | 2.52M | -1.65M | 21.70K | -183.57K | -455.08K | 2.86M | 2.84M |
| Net Income | -38.99M | -20.32M | -29.56M | -15.38M | -35.92M | -13.34M | -15.67M | -12.07M | -15.91M | -13.87M | -3.71M | -6.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.01% | -831.63% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| EPS | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EPS Diluted | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| Weighted Avg Shares Out | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
| Weighted Avg Shares Out (Dil) | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome community This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first...
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of...
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of...
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related Behaviors Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and...
Why Soleno Therapeutics Stock Is Skyrocketing Today
The U.S. Food and Drug Administration granted Breakthrough Therapy Designation for diazoxide choline. This designation is important to Soleno because it will help expedite the review process for its lead candidate.
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY,...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth...
Source: https://incomestatements.info
Category: Stock Reports